Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy are holding back sales at the pharma ...

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...

Eli Lilly and rival drugmaker Novo Nordisk are the leading companies in the GLP-1 space, but others are emerging. Among them is Pfizer; in September that company announced it would acquire Metsera, a ...

The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.

This Journal of Clinical Investigation review describes how glucagon-like peptide-1 (GLP-1)–based medicines reduce systemic and tissue inflammation through both weight-dependent and weight-independent ...

BOSTON — Health care professionals should use a broad range of tools to diagnose diabetic peripheral neuropathy, and ...

Insulin costs have declined over the past two years, and additional price cuts are expected in 2026. Medicare will lower prices for several diabetes drugs, including Januvia and Jardiance. Federal and ...

NHS patients in North Cumbria who need support with weight management are waiting more than a year, a consultant has said.

Type 1 diabetes is an autoimmune disease (typically arising in younger people) that occurs when your immune system attacks ...

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

Groundbreaking diabetes and weight loss drugs like Ozempic and Mounjaro are transforming treatment, offering significant weight loss. However, access ...